← All trials
NCT02500576
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 7, 2015
- Primary completion
- Aug 1, 2020
- Completion date
- Aug 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonOverall official - principal investigator
- MerckCollaborator
- Prometheus Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.